

Dojolvi

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pat	tient's Name:	
Pat	tient's ID:	Patient's Date of Birth:
Ph Sn/	ysician's Name:	NPI#:
Ph	ysician Office Telephone: quest Initiated For:	Physician Office Fax:
1.	What is the diagnosis? <i>Indicate ALL that apple</i> Carnitine palmitoyltransferase type 1 (CPT1) Carnitine palmitoyltransferase type 2 (CPT2) Carnitine-acylcarnitine translocase (CACT) of Very-long-chain acyl-CoA dehydrogenase (Vacylcarnitine translocase) Trifunctional protein (TFP) deficiency Other	deficiency deficiency deficiency LCAD) deficiency enase deficiency (LCHAD)
2.	What is the ICD-10 code?	
3.	Is the patient currently receiving treatment with	the requested medication? \square Yes \square No If No, skip to #6
4.	Is the patient currently receiving the requested r program? If Yes or Unknown, skip to #6 \(\sigma\) Y	medication through samples or a manufacturer's patient assistance les \(\bar{\text{U}} \) No \(\bar{\text{U}} \) Unknown
5.	improvement in cardiomyopathy, glycemic cont	as evidenced by disease stability or disease improvement (e.g., trol or exercise tolerance, or a reduction in episodes of a or hospitalizations)? Yes No No further questions
6.	Did the patient have the following elevated acyl to the patient's diagnosis? Yes No a. CPT1 deficiency: elevated C0; C0/C16 + C18 b. CPT2 and CACT deficiency: elevated C16 ar b. LCHAD and TFP deficiency: elevated C16-C c. VLCAD deficiency: elevated C14:1 and/or of	nd/or C18:1 DH and/or C18 and other acylcarnitines
7.	<i>B</i> ,	ng chart or laboratory documentation confirming low enzyme

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Dojolvi SGM - 6/2022.

8.	Does the patient have one or more known pathogenic mutations in CPT1A, SLC25A20, CPT2, acyl-CoA dehydrogenase very-long-chain (ACADVL), hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha (HADHA) or hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta (HADHB) gene? <i>ACTION REQUIRED: If Yes, attach supporting chart or laboratory documentation confirming pathogenic mutations by genetic testing.</i> \square Yes \square No		
9.	Has the patient been receiving a low-fat/high-carbohydrate diet and medium-chain triglyceride (MCT) supplementation (For example, MCT oil supplements, specialized infant or pediatric formula supplemented with MCT for LC-FAOD such as Lipistart, Monogen, Portagen, Enfaport, MCT Procal, MCT Oil, and Liquigen)? ☐ Yes ☐ No		
10.	How many hospitalizations and ER visits has the patient had within the past year due to rhabdomyolysis, cardiomyopathy or hypoglycemic episodes? ACTION REQUIRED: Attach supporting chart note(s)		
I at	ttest that this information is accurate and true, and that documentation supporting this		
	ormation is available for review if requested by CVS Caremark or the benefit plan sponsor.		
X_ Pre	escriber or Authorized Signature Date (mm/dd/yy)		

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Dojolvi SGM - 6/2022.